These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29944371)

  • 1. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.
    Bagal SK; Andrews M; Bechle BM; Bian J; Bilsland J; Blakemore DC; Braganza JF; Bungay PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; James K; Johnson E; Kitching L; Kraus ML; McAlpine I; Nagata A; Ninkovic S; Omoto K; Scales S; Skerratt SE; Sun J; Tran-Dubé M; Waldron GJ; Wang F; Warmus JS
    J Med Chem; 2018 Aug; 61(15):6779-6800. PubMed ID: 29944371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
    Bagal SK; Omoto K; Blakemore DC; Bungay PJ; Bilsland JG; Clarke PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; Johnson E; Fengas D; Kitching L; Kraus ML; McAlpine I; Nagata A; Waldron GJ; Warmus JS
    J Med Chem; 2019 Jan; 62(1):247-265. PubMed ID: 29672039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
    Skerratt SE; Andrews M; Bagal SK; Bilsland J; Brown D; Bungay PJ; Cole S; Gibson KR; Jones R; Morao I; Nedderman A; Omoto K; Robinson C; Ryckmans T; Skinner K; Stupple P; Waldron G
    J Med Chem; 2016 Nov; 59(22):10084-10099. PubMed ID: 27766865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.
    Shirahashi H; Toriihara E; Suenaga Y; Yoshida H; Akaogi K; Endou Y; Wakabayashi M; Takashima M
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2320-2326. PubMed ID: 31235262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
    McCarthy C; Walker E
    Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a Trk high affinity nerve growth factor receptor in the human prostate.
    Pflug BR; Dionne C; Kaplan DR; Lynch J; Djakiew D
    Endocrinology; 1995 Jan; 136(1):262-8. PubMed ID: 7828539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
    J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Trk family of neurotrophin receptors.
    Barbacid M
    J Neurobiol; 1994 Nov; 25(11):1386-403. PubMed ID: 7852993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
    Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential dependency of cutaneous mechanoreceptors on neurotrophins, trk receptors, and P75 LNGFR.
    Fundin BT; Silos-Santiago I; Ernfors P; Fagan AM; Aldskogius H; DeChiara TM; Phillips HS; Barbacid M; Yancopoulos GD; Rice FL
    Dev Biol; 1997 Oct; 190(1):94-116. PubMed ID: 9331334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
    Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
    Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
    Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
    Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.
    Steinig AG; Li AH; Wang J; Chen X; Dong H; Ferraro C; Jin M; Kadalbajoo M; Kleinberg A; Stolz KM; Tavares-Greco PA; Wang T; Albertella MR; Peng Y; Crew L; Kahler J; Kan J; Schulz R; Cooke A; Bittner M; Turton RW; Franklin M; Gokhale P; Landfair D; Mantis C; Workman J; Wild R; Pachter J; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4381-7. PubMed ID: 23773865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotrophins in cultured cells from periodontal tissues.
    Kurihara H; Shinohara H; Yoshino H; Takeda K; Shiba H
    J Periodontol; 2003 Jan; 74(1):76-84. PubMed ID: 12593600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of neurotrophin/receptor interactions with a gD-flag-modified quantitative kinase receptor activation (gD.KIRA) enzyme-linked immunosorbent assay.
    Sadick MD; Galloway A; Shelton D; Hale V; Weck S; Anicetti V; Wong WL
    Exp Cell Res; 1997 Aug; 234(2):354-61. PubMed ID: 9260905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural determinants of Trk receptor specificities using BDNF-based neurotrophin chimeras.
    Lai KO; Glass DJ; Geis D; Yancopoulos GD; Ip NY
    J Neurosci Res; 1996 Dec; 46(5):618-29. PubMed ID: 8951673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular localization of Pan-trk immunoreactivity and trkC mRNA in the enteric nervous system.
    Sternini C; Su D; Arakawa J; de Giorgio R; Rickman DW; Davis BM; Albers KM; Brecha NC
    J Comp Neurol; 1996 May; 368(4):597-607. PubMed ID: 8744446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas.
    Perez-Pinera P; Hernandez T; García-Suárez O; de Carlos F; Germana A; Del Valle M; Astudillo A; Vega JA
    Mol Cell Biochem; 2007 Jan; 295(1-2):19-26. PubMed ID: 16862449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.